Edgewise Therapeutics: Pay

Edgewise Therapeutics paid its 7 named executives $27.3M in total in FY2025 (Dec). CEO Kevin Koch, Ph.D. was paid $7.4M of that.

Pay$100 in the stock at the end of FY21 → $162
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Kevin Koch, Ph.D.President and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Robert Blaustein, M.D., Ph.D.Former Chief Development Officer
FY2025 (Dec)
1 year
Michael P. NofiChief Financial Officer
FY2025 (Dec)
1 year
Behrad Derakhshan, Ph.D.Chief Operating Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Joanne M. Donovan, M.D., Ph.D.Chief Medical Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Co-Founder andChief Scientific Officer
FY2025 (Dec)
1 year
R. Michael CarruthersFormer Chief Financial Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 8 peers with pay on file was $10.7M. CEO pay of Edgewise Therapeutics for that year is not on file.

  1. 1Scholar Rock Holding
  2. 2Cogent Biosciences
  3. 3Protagonist Therapeutics
  4. 4Enliven Therapeutics
  5. 5IDEAYA Biosciences
  6. 6Kymera Therapeutics
  7. 7Beam Therapeutics
  8. 8Denali Therapeutics
  9. 9Edgewise TherapeuticsNot disclosed
  10. 1089bioNot disclosed
  11. 11Aerovate TherapeuticsNot disclosed
  12. 12Akero BiosciencesNot disclosed
  13. 13Arcus BiosciencesNot disclosed
  14. 14Avidity BiosciencesNot disclosed
  15. 15Dyne TherapeuticsNot disclosed
  16. 16Janux TherapeuticsNot disclosed
  17. 17Keros TherapeuticsNot disclosed
  18. 18MorphicNot disclosed
  19. 19Pliant TherapeuticsNot disclosed
  20. 20Rocket PharmaceuticalsNot disclosed
  21. 21Zentalis PharmaceuticalsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.